Japan’s Ministry Reviews Thalidomide For Multiple Myeloma
This article was originally published in PharmAsia News
Executive Summary
The Ministry of Health, Labor and Welfare began a review panel meeting Aug. 26 to consider thalidomide as a treatment for multiple myeloma, on condition that adverse event prevention methods are fully addressed. The MHLW panel will consider safety measures put forth by pharmaceutical companies, such as registration requirements for pharmacists, physicians and patients and establishment of a third party to monitor compliance. Upon completion of the review the drug could be launched as early as the end of the year. Japan has 13,000-14,000 multiple myeloma patients. Thalidomide is approved to treat multiple myeloma in 17 countries. (Click here for more - Japanese language)
You may also be interested in...
Japan Re-approves Thalidomide For Cancer Treatment
TOKYO - Japan's Ministry of Health, Labor and Welfare has approved re-listing thalidomide, which Japan banned in 1962 for causing serious human deformations, to be marketed by Fujimoto Pharmaceutical, officials of the ministry's Pharmaceutical and Food Bureau and the Insurance Bureau confirmed Oct. 7
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.